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and exit) were below 10 % (TLD and SEM
detectors) with the exceptions for the neck
at lateral and for the lungs at AP/PA fields
where the errors exceeded 10 %.
Conclusions: For the group of patients
the per cent deviations exceeded 10%
for the neck exit in lateral fields and for
the lung exit in anterior - posterior fields.
Standard deviations exceeded 10%
at the neck and lung exits in lateral fields
and at the lung exit in anterior - posterior
fields.
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Cord blood is a rich source of primitive
hemopoietic stem cells. In clinical hema-
tology it is transplanted instead of bone
marrow or peripheral blood stem cells.
The Institute of Hematology and Blood
Transfusion in Warsaw has had a Cord
Blood Bank (WACB) since 1997. WACB
collaborates with Eurocord Transplant
Group and with Bone Marrow Donors
Worldwide transfering data on frozen CB
intended for transplantation. During 1997 -
2000, a total of 159 unrelated and 29 re-
lated cord blood units were collected.
More than 70% of transplants of CB were
perfomed in pediatric recipiens it is nece-
ssary to reduce its volume of storage
of CB units. Separation techniques reduce
sample volume to ± 20 ml. Sedimentation
methods reduce the number of RBC to be
infused. RBC depletion reduces the risk
of incompatibile reaction. Sedimentation
reduces side-effects of the DMSO (dimethyl
sulfoxide) cytotoxity (DMSO volume is re-
duced to 4 ml).
The aim of our study was to evaluate
methods of isolating leukocytes from cord
blood within a closed system. Two me-
thods of isolation have been tested: 6%
hydroxyethyl starch in 0,9% NaCI and 3%
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gelatin in 0,9% NaCI (Gelafundine, Braun).
Centrifugation and sedimentation methods
have been used. The final volume of cord
blood was 20 ml for each unit. The best
results were obtained for sedimentation.
With 3% gelatin sedimentation 75,1%
WBC and 81,3% CD34+ were recovered,
while the waste of RBC was 97,2%;
with 6% HES sedimentation the results
were: 65%; 90,3%, and 80,5% respe-
ctively. The results of our centrifugation
methods revealed a great loss of proge-
nitor cells (approx. 40%). 6% HES and 3%
gelatin are approved for clinical use,
therefore sedimentation methods based
on these media are safe for recipients.
Furthermore, the use of closed system
recommended by Eurocord Transplant,
prevents bacterial contamination.
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Purpose: We present the role of detailed
and frequent monitoring of hematopoietic
chimerism in prediction of post-transplant
clinical outcome and our initial experience
with adoptive immunotherapy (AI) in pre-
vention and treatment of relapse in children
after allogeneic hematopoietic stem cell
transplantation (HSCT) for leukemia.
Materials and methods: Between
1/1997 and 12/2000 we performed a total
of 46 unmanipulated allogeneic HSCT
from HLA-identical siblings (MSD;23)
or matched unrelated donors (MUD;23)
in 43 consecutive children with hema-
tological malignancies (ALL 16, AML 15,
CML 5, MDS 6, JMML 3, CMML 1) with
a median age of 10,5 years. We have
analyzed hematopoietic chimerism in peri-
pheral blood samples using polymerase
chain reaction (peR) of variable number
819
of tandem repeats (VNTR) with a ma-
ximum sensitivity of 0,5% in 44 evaluable
follow-ups. AI was used in 11 patients/12
follow-ups (ALL 3, AML 5, CML 2, JMML
1/2). The treatment was started on the ba-
sis of increasing mixed chimerism
(inMC;7), in molecular relapse (1) or in he-
matological relapse (4). Withdrawn
of post-transplant immunosuppression
was performed in 9 patients, 5 patients
received second-line therapy by donor
lymphocyte infusion (DLI) and in 3 follow-
ups DLI was applied as a front-line
therapy. AI was combined with
chemotherapy (CHT) in 2 children. CD3+
doses varied between 1x1 05 and 2,4x108/kg
body weight according to type of donor
and indication for DLI.
Results: Complete donor chimerism
(CC) characterized by the disappearance
of recipient cells until day (0)+28
and sustained emergence of donor cells
was documented in 25/44 follow-ups.
Mixed chimerism (MC) characterized
by the re-emergence or persistence of re-
cipient cells after 0+28 was found
in 19/44 follow-ups. Transient MC (trMC)
was detected in 7, inMC in 12 follow-ups,
respectively. Transplant related mortality
(TRM) until 0+100 was 7/25 in CC
and 1/19 in MC group, respectively;
36 patients were therefore evaluable
for relapse free survival (RFS). At a me-
dian follow-up of 19 months (range
2 to 51 months) RFS for CC group was
17/18, whilst that for MC group was 7/18.
Hematological relapse was documented
in 1/7 children with trMC, in 1 patient
molecular relapse was detected and AI
was started before the appearance
of trMC. InMC was followed by hema-
tological relapse in 9/12 follow-ups,
3/12 patients with inMC responded to AI
and re-achieved CC. Complete response
to AI was defined as sustained recurrence
of CC and CCR was documented
in 4/12 children (1 AML, 2 CML, 1 JMML)
at a median follow-up of 30 months (range
15 to 40 months), 1 patient (ALL) achieved
CC but died due to severe graft-versus-
host disease. Three patients (2 AML,
1 JMML) showed transient decrease
or disappearance of MC and developed
hematological relapse SUbsequently, 8, 9
and 20 months after the first intervention
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with AI. No response was seen
in 4/12 follow-ups (2 ALL, 2 AML).
Conclusions: Detailed and frequent
monitoring of HC allows identification
of patients with high risk for hematological
relapse and therefore indicated for AI.
At least in some children with leukemia
it is possible to prevent hematological
relapse using AI when the intervention
comes early.
This work was suppol1ed by grants IGA-
MZ GR NC 6512-3 and IGA-MZ GR NC
5902-3.
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Purpose: To evaluate the preliminary
results obtained with donor CD3
lymphocyte infusion (DLI) and interferon-a
(INF-u) in children with hematological CML
relapse occurring after allogeneic bone
marrow transplantation (allo-BMT)
Patients and methods: Between 1998-
2000 three children with CML underwent
allo-BMT from HLA-identical sibling and
developed hematological leukemia
relapse, which has been treated with DLI
and INF-a.
Conclusion: DLI + INF-a seems to offer
relatively effective and safe therapeutic
option for advanced types of CML relapse
occurring after allo-BMT in children, but
further long lasting follow-up is necessary
to define its place in management of post-
transplant leukemia relapse.
This work was suppol1ed by the State
Committee for Scientific Research -
Project No 6 POSE 050 21.
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